ArticleInternal medicine (Tokyo, Japan)2026
Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin. Subsequent treatment with oral cyclosporine (CsA), carefully dosed for liver cirrhosis, achieved complete hematologic recovery. This report details a successful management strategy for this rare, life-threatening irAE, suggesting the potential utility of CsA after initial therapies fail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.